Skip Navigation



Rheumatology Advance Access published online on February 3, 2006
Rheumatology, doi:10.1093/rheumatology/kel030
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
45/8/982    most recent
kel030v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Saurenmann, R. K.
Right arrow Articles by Silverman, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saurenmann, R. K.
Right arrow Articles by Silverman, E. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Received September 20, 2005
Accepted January 6, 2006

Original Papers

Tumour necrosis factor {alpha} inhibitors in the treatment of childhood uveitis

R. K. Saurenmann 1 *, A. V. Levin 2, J. B. Rose 1, S. Parker 1, T. Rabinovitch 3, P. N. Tyrrell 1, B. M. Feldman 1, R. M. Laxer 4, R. Schneider 1, and E. D. Silverman 1

1 Division of Rheumatology, Hospital for Sick Children, Toronto, Canada
2 Department of Ophthalmology and Vision Sciences, Hospital for Sick Children, Toronto, Canada
3 North Toronto Eye specialists, Toronto, Canada
4 Departments of Paediatrics and Medicine, Hospital for Sick Children, Toronto, Canada

* To whom correspondence should be addressed.
R. K. Saurenmann, E-mail: traudel.saurenmann{at}kispi.unizh.ch


  Abstract

Objective. To describe the efficacy of anti-TNF-{alpha} agents in the treatment of childhood uveitis.

Methods. We performed a retrospective chart review of all children with uveitis treated with TNF-{alpha} blockers at The Hospital for Sick Children, Toronto.

Results. Twenty-one children with uveitis were treated with the anti-TNF-{alpha} agents etanercept (11 patients) and infliximab (13 patients), resulting in 24 treatment courses. All patients had persistently active uveitis despite treatment with at least one standard immunosuppressive drug before the start of anti-TNF-{alpha} therapy. Six of 21 patients (29%) had idiopathic uveitis. In the other 15 patients, the underlying disease was juvenile idiopathic arthritis in 12 (57%), Behçet disease in two (9%) and sarcoidosis in one (5%). Response to etanercept treatment was good in 27%, moderate in 27% and poor in 45% of patients. Response to infliximab treatment was good in 38%, moderate in 54% and poor in 8% of patients. The difference in the percentage of patients with a moderate or good response was statistically significant (P=0.0481). We also observed a lower rate of complications, such as new-onset or worsening glaucoma or cataract in the infliximab-treated group.

Conclusion. Anti-TNF-{alpha} treatment was beneficial in a high percentage of patients with childhood uveitis refractory to standard immunosuppressive treatment. Infliximab resulted in better clinical responses with less ocular complications than etanercept.

Keywords: Biological agents; Eye diseases; Juvenile idiopathic arthritis; Outcome assessment..
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
H. Foster and A. V. Ramanan
'The eyes have it!' The need to improve awareness and access to early ophthalmological screening for juvenile idiopathic arthritis associated uveitis
Rheumatology, April 1, 2009; 48(4): 330 - 331.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
G. Simonini, M. E. Zannin, R. Caputo, F. Falcini, M. de Martino, F. Zulian, and R. Cimaz
Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis
Rheumatology, October 1, 2008; 47(10): 1510 - 1514.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
T. Cobo-Ibanez, M. del Carmen Ordonez, S. Munoz-Fernandez, R. Madero-Prado, and E. Martin-Mola
Do TNF-blockers reduce or induce uveitis?
Rheumatology, May 1, 2008; 47(5): 731 - 732.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
P. Tynjala, K. Kotaniemi, P. Lindahl, K. Latva, K. Aalto, V. Honkanen, and P. Lahdenne
Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis
Rheumatology, March 1, 2008; 47(3): 339 - 344.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
S. Guillaume-Czitrom, C. Berger, C. Pajot, B. Bodaghi, B. Wechsler, and I. Kone-Paut
Efficacy and safety of interferon-{alpha} in the treatment of corticodependent uveitis of paediatric Behcet's disease
Rheumatology, October 1, 2007; 46(10): 1570 - 1573.
[Abstract] [Full Text] [PDF]

Home page
 AAP Grand RoundsHome page
S. C. Li
Which Children with Juvenile Idiopathic Arthritis Are at Risk for Blindness?
AAP Grand Rounds, June 1, 2007; 17(6): 65 - 65.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
P. P. Sfikakis, N. Markomichelakis, E. Alpsoy, S. Assaad-Khalil, B. Bodaghi, A. Gul, S. Ohno, N. Pipitone, M. Schirmer, M. Stanford, et al.
Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations
Rheumatology, May 1, 2007; 46(5): 736 - 741.
[Full Text] [PDF]

Home page
 Br J OphthalmolHome page
A. M Mansour
Adalimumab in the therapy of uveitis in childhood
Br J Ophthalmol, March 1, 2007; 91(3): 274 - 276.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.